Identification of novel cell glycolysis related gene signature predicting survival in patients with endometrial cancer

Abstract

BackgroundEndometrial cancer (EC) is one of the three major gynecological malignancies. Numerous biomarkers that may be associated with survival and prognosis have been identified through database mining in previous studies. However, the predictive ability of single-gene biomarkers is not sufficiently specific. Genetic signatures may be an improved option for prediction. This study aimed to explore data from The Cancer Genome Atlas (TCGA) to identify a new genetic signature for predicting the prognosis of EC.MethodsmRNA expression profiling was performed in a group of patients with EC (n = 548) from TCGA. Gene set enrichment analysis was performed to identify gene sets that were significantly different between EC tissues and normal tissues. Cox proportional hazards regression models were used to identify genes significantly associated with overall survival. Quantitative real-time-PCR was used to verify the reliability of the expression of selected mRNAs. Subsequent multivariate Cox regression analysis was used to establish a prognostic risk parameter formula. Kaplan–Meier survival estimates and the log‐rank test were used to validate the significance of risk parameters for prognosis prediction.ResultNine genes associated with glycolysis (CLDN9, B4GALT1, GMPPB, B4GALT4, AK4, CHST6, PC, GPC1, and SRD5A3) were found to be significantly related to overall survival. The results of mRNA expression analysis by PCR were consistent with those of bioinformatics analysis. Based on the nine-gene signature, the 548 patients with EC were divided into high/low-risk subgroups. The prognostic ability of the nine-gene signature was not affected by other factors.ConclusionA nine-gene signature associated with cellular glycolysis for predicting the survival of patients with EC was developed. The findings provide insight into the mechanisms of cellular glycolysis and identification of patients with poor prognosis in EC.

RETRACTED: Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer

“…Several research studies have focused on the systematic analysis of glycolysis and tumors, including glioblastoma (15), liver cancer (16), and endometrial cancer (17). However, comprehensive analysis of the interrelation between glycolysis, immune infiltration, and clinical prognosis in GC patients is lacking.…”

A glycolysis-based 4-mRNA signature correlates with the prognosis and cell cycle process in patients with bladder cancer

“…A three-gene glycolytic signature (MET, B3GNT3 and SPAG4) can act as an independent factor for generating a prognosis for patients with pancreatic ductal adenocarcinoma [22]. A nine-gene signature associated with cellular glycolysis was a potent indicator for the prediction of overall survival in patients with endometrial cancer [23]. The glycolysis score represented by expression of ten glycolytic genes predicted unfavorable clinical outcome for patients with glioblastoma and was closely related to mesenchymal subtype and mutation of IDH1 in glioblastoma [24].…”

The AKR1C3/AR‐V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression

“…breast cancer and leukaemia. [22][23][24][25][26][27][28] On the other hand, B4GALT1 is frequently methylated or down-regulated in colorectal cancer and endometrial cancer 29,30 and can be used to predict patient outcomes. In this study, based on the analysis of TCGA database, we Taken together, this study identified AKR1C3 as a new critical regulator that increases the expression and transcriptional activity of AR-V7 by forming a complex to inhibit its protein degradation.…”